Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection

Stock Information for PAVmed Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PAVmed Inc.

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
Lucid Diagnostics Launches New Corporate Website
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
4,000th Firefighter Undergoes Lucid Diagnostics' EsoGuard® Esophageal Precancer Testing
PAVmed Provides Business Update and First Quarter 2024 Financial Results
Lucid Diagnostics Provides Business Update and First Quarter 2024 Financial Results
Legacy Sponge-on-a-String Esophageal Cell Collection Device Subject of Class II FDA Recall

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.